Skip to main content
. Author manuscript; available in PMC: 2022 May 13.
Published in final edited form as: J Med Chem. 2021 Apr 22;64(9):5577–5592. doi: 10.1021/acs.jmedchem.0c02041

Figure 2: Prior Examples of the Pyrrolidine Bis-Cyclic Guanidine Scaffold.

Figure 2:

Compounds TPI1818-101 and TPI1818-109 were identified screening pyrrolidine bis-cyclic guanidine scaffold mixtures in an in vivo antinociception assay paradigm.63 Compounds 34 and 330 were identified from screening pyrrolidine bis-cyclic guanidine scaffold mixtures against methicillin-resistant Staphylococcus aureus, and also showed bactericidal activity against vancomycin-resistant Enterococcus faecalis.64